1. Introduction {#sec1}
===============

Fructose is a monosaccharide that is present in significant amounts in fruits, honey, table sugar (sucrose has a 50% fructose content), and soft drinks sweetened with high fructose corn syrup (55% fructose content) \[[@B1]\]. It is the sweetest and more soluble natural carbohydrate \[[@B2]\].

Due to its low cost \[[@B3]\], it was adopted by the soft drink industry, and nowadays many sugar-sweetened beverages and fruit juice drinks contain high amounts of fructose \[[@B4]\].

To give an example of the current data about fructose added beverages intake, sugar-sweetened soft drink consumption increased 400% in Brazilian metropolitan areas from 1974--1975 to 2002--2003, corresponding to an increase of 0.4% to 2.1% of the total calories consumed daily \[[@B5]\]. In the Institute of Medicine (IOM) macronutrient report, the committee recommended a maximal intake of ≤ 25% of energy from added sugars. In a recent survey thirteen percent of the population had added sugars intake \> 25% \[[@B6]\].

The intake of sweetened beverages high in fructose increased by \>1000% between 1970 and 1990 \[[@B7]\]. In 2013, 68% of all packaged foods and beverages purchased by a nationally representative sample of United States households contained caloric sweeteners \[[@B8]\].

Unlike glucose that has a glycemic index of 59, fructose has a lower glycemic index of 20 \[[@B2]\]. In addition, it induces less insulin secretion compared to glucose \[[@B9]\]. Because of these characteristics, fructose has been recommended as a substitute for glucose in patients with diabetes \[[@B10], [@B11]\].

However, this recommendation has been challenged by experimental and epidemiological evidence that excessive fructose intake may have a role in the development of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus (T2DM) \[[@B12], [@B13]\]. Currently, it is well known that high fructose intake favors the development and progression of kidney disease \[[@B14]\]. For example, rats fed with a high fructose diet developed tubular injury and interstitial inflammation and fibrosis, associated with an increased oxidative stress \[[@B15]\]. A similar study showed that a high fructose diet accelerated the progression of renal damage, causing glomerular sclerosis, cellular infiltration, tubular dilatation, and atrophy \[[@B16]\]. An association between the intake of more than two sugary soft drinks per day and prevalence of albuminuria was also observed in a study analyzing data from the National Health and Nutrition Examination Survey (NHANES) \[[@B17]\].

The primary aim of this study was to evaluate the association between fructose intake and albuminuria. The secondary aims were to evaluate the association between fructose intake and the following: uric acid, glycemic control, creatinine clearance, lipid profile, and anthropometric variables, in Mexican-Mestizo subjects with T2DM. We hypothesized that in subjects with T2DM, increased fructose intake is associated with greater albuminuria; our secondary hypothesis was that a higher fructose intake is associated with a higher uric acid serum concentration, lower creatinine clearance, higher triglycerides, and higher BMI.

2. Material and Methods {#sec2}
=======================

This was a single center cross-sectional study. Subjects were recruited from the Diabetes Clinic at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, a nonprofit, public, and university-affiliated hospital in Mexico City, between June 2013 and March 2015. We included subjects of both genders between 18 and 70 years old, with T2DM, with a median of 16 \[[@B3]--[@B36]\] years of duration of diabetes, and albuminuria between 0 and 6000 mg/day determined in the prior three months. If the subjects had albuminuria ≥30 mg/day, they needed to have documented diabetic retinopathy to confirm that nephropathy is due to diabetes mellitus 2 and be able to complete the prospective diary of food ingestion. All subjects who presented albuminuria determination within 3 months of enrollment were invited to participate. This albuminuria determination was used as the outcome variable in our statistical analysis. Exclusion criteria included a body mass index (BMI) \>40 kg/m^2^, glomerulonephritis or nondiabetic nephropathy (with the exception of hypertensive kidney disease), autoimmune diseases, liver diseases, infection with hepatitis C virus, HIV virus, other types of diabetes such as type 1 diabetes, creatinine clearance \<15 mL/min, the coexistence of other diseases with poor short-term prognosis, acute infection, pregnancy or lactation, and hospitalization in the last three months.

Patients underwent a nutritional and clinical assessment. To calculate the median daily fructose intake, a prospective diary of food ingestion for 3 days (2 week-days and one weekend day) was requested. The prospective diary consisted of a food registry that was filled prospectively for 1 week (we told the participants of the study to write down all the foods and beverages they ingested on 2 week-days and one weekend day); an example of this approach was used in another investigation \[[@B18]\]. Total fructose intake was estimated as the sum of the free fructose plus the fructose contained in sucrose (sucrose is composed of 50% glucose and 50% fructose). The fructose content of food was obtained from the tables of free fructose and sucrose content of the Australian Government \[[@B19]\] and of the United States Department of Agriculture (USDA Food Composition Databases) \[[@B20]\]. Two certified nutritionists (MMS and IMM), blinded to each other, calculated the daily fructose intake and the average of the 2 calculations was used for further analyses. The correlation between the 2 nutritionists was *ρ*=0.94, p\<0.001.

A complete clinical evaluation was performed including past medical history, family history, and current medications. Blood pressure was measured considering the mean of two determinations after seating for at least 5 minutes \[[@B21]\]. Mean arterial pressure (MAP) was calculated with the traditional formula: (systolic blood pressure *∗* 0.33) + (diastolic blood pressure *∗* 0.66) \[[@B22]\]. Anthropometric variables were measured using standardized techniques; these included height, weight, waist and hip circumferences, and quantification of body fat using bioelectrical impedance with the Jawon scale model IOI 353 - JMW160 ®. BMI was calculated using the standard equation, weight/height^2^ (kg/m^2^).

After at least eight-hour fasting, glucose, lipid profile (total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides), creatinine, uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albuminuria in a 24 h urine collection were measured using an automated analyzer (Synchron CX Beckman, Fullerton CA). LDL-cholesterol (LDL) was estimated by the Friedewald equation (LDL= total cholesterol - HDL - triglycerides /5)\[[@B23]\]. Glycated hemoglobin (A1c) was measured using HPLC (Variant II Turbo, Biorad), certified by the National Glycohemoglobin Standardization Program (NGSP). Creatinine clearance was calculated using the CKD-EPI equation \[[@B24]\]. All samples were measured in the Laboratorio Central of Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (<http://www.innsz.mx/opencms/contenido/departamentos/labcentral/>). 100% of the samples are certified by the College of American Pathologists (71893-07-01) [Figure 4](#fig4){ref-type="fig"}.

2.1. Ethics {#sec2.1}
-----------

The study was approved by the Comite de Etica en Investigacion del Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Ref. 939). Written informed consent was obtained from all participants before enrollment.

2.2. Statistics {#sec2.2}
---------------

The sample size was determined using the correlation formula. Considering a type 1 error of 5%, a 90% power, and a correlation of 0.25 between albuminuria and fructose intake, a sample of 134 patients was estimated. Numeric variables were examined for normality using the Shapiro-Wilk test. Accordingly, variables with a normal distribution are expressed as means and standard deviation, and non-normally distributed variables as medians and interquartile range.

We grouped fructose intake based on the proposal that 25 g/day (\~5% of the total daily calories) or lower is the desired level \[[@B25]\]. Therefore, we divided the population into group 1, subjects that consumed less than 25 g day, and group 2, subjects who consumed 25 g day or more.

Comparisons between men and women were performed using independent Student\'s T or U-Mann-Whitney tests, as appropriate. The association between the daily fructose intake and albuminuria, uric acid, lipids, and HbA1c concentrations was evaluated with Spearman correlation coefficients. A partial correlation analysis adjusting for weight and waist circumference was also performed.

A linear regression analysis was performed to evaluate the independent association of the daily fructose intake and albuminuria. The dependent variable was albuminuria and the independent variables included in the model were the daily fructose intake, BMI, A1c, use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), and the MAP.

To examine the association of fructose intake in the patients with presence of albuminuria, a subanalysis in the group of individuals with albuminuria between 30 and 3500 mg/24 h was also performed.

A two-sided p value \<0.05 was considered statistically significant. Analyses were performed with the IBM SPSS Statistics version 21.0, US.

3. Results {#sec3}
==========

A total of 773 subjects were assessed, of which 143 subjects were recruited; the main exclusion criteria were the presence of comorbidities such as rheumatoid arthritis, systemic lupus erythematosus, and liver disease. Seven subjects were excluded from the analysis following recruitment for other causes, leaving 136 subjects that were analyzed. The flow chart of patients included in the study is shown in [Figure 1](#fig1){ref-type="fig"}.

3.1. Baseline Characteristics of the Studied Population {#sec3.1}
-------------------------------------------------------

The baseline characteristics of the studied population are summarized in [Table 1](#tab1){ref-type="table"}. The subjects analyzed included 69 (50.7%) men and 67 (49.3%) women (the comparison of variables by sex is presented in Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}). The population was divided into the ones that had low fructose intake (\<25 g/day) and the ones that had high fructose intake (≥ 25 g/day) ([Table 1](#tab1){ref-type="table"}). More than 85% of participants reported a family history of T2DM in both groups (p=0.891). The mean age was similar in the low and in the high fructose intake groups (59±9.46 and 59±7.41 years, p=0.924). Current smoking was reported in 17.8% of the people with low fructose intake and in 19.6% in the group of high fructose intake (p= 0.799).

The MAP did not differ between groups (90±13.26 versus 92±11.4 mmHg, p= 0.472).

Mean BMI (29.8±4.2 versus 29.3±4.2 kg/m^2^) and waist circumference (100.4±10.8 versus 101.6±12.4 cm) were similar in low and high fructose intake groups with no statistical significance (p=0.558, p=0.574, respectively) as well as the waist-hip ratio (WHR) with 0.95±0.08 versus 0.97±0.07, p=0.084, comparing both groups. However, the body fat percentage was higher in low fructose intake compared to high fructose intake (33.8±7.6 versus 30.4±9, p \<0.033).

Fasting glucose concentration was not statistically significant different between the groups (151.9±61.34 versus 160.4±69.45 mg/dL, p= 0.462). Nevertheless, HbA1c was significantly higher in the group with high fructose intake (8.6±1.61% versus 9.6±2.1%, p= 0.003). Serum creatinine was similar in both groups (1.08±93 versus 1.25±74 mg/dL, p= 0.281), but creatinine clearance was decreased in the group with high fructose intake (94.9±36.8 versus 76.5±30.98 mL/min, p=0.014). BUN and uric acid were also higher in the subjects with high fructose intake (19.6\[13.6-21.3\] versus 24.6\[15.5-27.6\] md/dL, p= 0.022 and 6.27±1.8 versus 7.2±1.5 mg/dL, p=0.012 respectively). Median albuminuria (60.8 \[12.8-228.5\] versus 232.2 \[27.2-1273.0\] mg/day, p 0.002) was also higher in subjects with high fructose intake compared to the \<25 g/day fructose intake.

Both total cholesterol and LDL-cholesterol were significantly higher in the group with higher fructose intake (167.2±33.3 versus 186.5±44.4 mg/dL, p=0.005, and 91.5±28.7 versus 106.6±35.9 mg/dL, p=0.010, respectively). However, serum triglycerides (162.3\[101.2-195.5\] versus 162.3\[101.2-195.5\] mg/dL, p=0.936) and HDL-cholesterol (45.1±10.6 versus 47.5±12.7 mg/dL, p=0.230) were similar between the groups.

In relation to treatment, 77% of subjects were receiving insulin, 82% metformin, 34% an angiotensin-converting-enzyme (ACE) inhibitor, and 12% an angiotensin II receptor blocker (ARB). Insulin use was higher in the high fructose group, but for the other treatments there were no differences between the low and high fructose groups ([Table 1](#tab1){ref-type="table"}).

In supplementary tables [1](#supplementary-material-1){ref-type="supplementary-material"}[to 3](#supplementary-material-1){ref-type="supplementary-material"} we show the subjects stratified by gender.

3.2. Calorie and Fructose Intake {#sec3.2}
--------------------------------

Total energy (calorie) intake was 1585±558.4 kcal/day in the subjects with low fructose intake and 2125±588.9 kcal/day in the subjects with high fructose intake, p\<0.001. The median fructose intake was 14.3±6.3 g/day in the low fructose intake group and 36.4±10.4 g/day in high fructose intake group (p\<0.001). The macronutrient distribution is summarized in [Table 2](#tab2){ref-type="table"}. The analysis by sex is shown in [Table 2](#supplementary-material-1){ref-type="supplementary-material"} of the Supplementary Materials.

3.3. Correlation Analysis {#sec3.3}
-------------------------

In [Table 3](#tab3){ref-type="table"}, we present the correlations between albuminuria with clinical and metabolic variables in all the studied subjects (n=136). We found a positive, significant association between daily fructose intake and albuminuria (*ρ*= 0.178, p=0.038). Other variables significantly associated with albuminuria were BMI (*ρ*= 0.170, p=0.048), MAP (*ρ*= 0.280, p=0.001), A1c (*ρ*= 0.197, p=0.022), and triglycerides (*ρ*= 0.219, p=0.010).

In [Table 4](#tab4){ref-type="table"}, we show the correlation analysis for the subjects with albuminuria between 30 and 3500 mg/day. There was a significant positive association between fructose intake and albuminuria (*ρ*= 0.238, p=0.027).

In [Figure 2](#fig2){ref-type="fig"} the association between fructose intake and albuminuria is illustrated in all the studied subjects (n=136). The association between fructose intake and albuminuria in subjects with albuminuria between 30 to 3500 mg/day is presented in [Figure 3](#fig3){ref-type="fig"}.

3.4. Multiple Linear Regression Analysis {#sec3.4}
----------------------------------------

To adjust for confounding variables, we performed a multiple linear regression analysis considering albuminuria as the dependent variable (subjects with 30 to 3500 mg/day) and fructose intake, BMI, HbA1c, use of ACE inhibitors and/or ARB, and MAP as independent variables. We found a significant and independent association between fructose intake and albuminuria (*β*= 13.96, p=0.006) ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

This study evaluated the association between fructose intake and the following: albuminuria, glycemic control, and lipid profile, in subjects with T2DM. A significant positive association between fructose intake and albuminuria in subjects with T2DM was found. This association persisted after the adjustment for significant confounders. Fructose intake was similar between men and women, but albuminuria was higher in men than in women as previously reported \[[@B26]\] (Supplementary Tables [1](#supplementary-material-1){ref-type="supplementary-material"} and [3](#supplementary-material-1){ref-type="supplementary-material"}). However, we found greater albuminuria and uric acid concentration in diabetic subjects on a high fructose diet compared to a low fructose diet.

The proposed mechanism that could explain why a high fructose diet could be associated with kidney damage is the following: Fructose is transported passively in the intestines by the GLUT5 transporter \[[@B27]\] and then is phosphorylated by ketohexokinase in an unregulated manner, causing hepatic ATP depletion and decreased protein synthesis, with inflammatory and prooxidant changes \[[@B28]--[@B30]\]. In addition, ATP depletion with nucleotide turnover favors uric acid synthesis \[[@B31]\] and causes the activation of the carbohydrate-responsive element-binding protein (ChREBP), a transcription factor that induces the expression of genes implicated in triglyceride synthesis \[[@B32]\]. Fructose also augments triglyceride synthesis by its metabolism into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, which constitutes the glycerol structural base of triglycerides \[[@B33], [@B34]\], and initiates glycolysis and production of acetyl-CoA, required for*de novo* lipogenesis and fatty acid synthesis \[[@B35]\]. Recently it has been demonstrated that sorbitol can be converted to fructose (fructoneogenesis) in the proximal tubule and then metabolized by the ketohexokinase, leading to ATP depletion, proinflammatory cytokine expression, and oxidative stress \[[@B36]\].

Some authors suggest that diabetic nephropathy could be aggravated by oxidative stress \[[@B37]\];in addition, both high uric acid \[[@B37]\] and high triglycerides \[[@B38]\] have been associated also with diabetic nephropathy. Therefore we think that a high fructose diet increases oxidative stress, uric acid and triglycerides, and deteriorate kidney function and increases albuminuria in subjects with T2DM.

A high fructose diet has been shown to induce renal damage in rats (3). The proposed mechanisms include synthesis of reactive oxygen species secondary to ATP depletion and uric acid generation with the production of chemokines and proinflammatory molecules \[[@B29], [@B30], [@B39]\]. Another study showing the deleterious effect of a high fructose diet was made in*Rhesus* monkeys that received a daily beverage containing 75 g of fructose for 12 months; those monkeys developed an increase in body fat, insulin resistance, and dyslipidemia. Furthermore, 4 monkeys (15%) developed diabetes \[[@B40]\]. Similar deleterious effects were observed in humans that received fructose-sweetened beverages (25% of the energy requirement) for 10 weeks compared with a group receiving glucose-sweetened beverages \[[@B13]\]. In an additional study, subjects who consumed a fructose-sweetened beverage had greater visceral adiposity, higher triglycerides, increased*de novo* lipogenesis, higher low-density lipoproteins (LDL) cholesterol, Apo B-100, small dense LDL, oxidized LDL, higher concentrations of glucose and insulin, and lower insulin sensitivity \[[@B41]\].

There is evidence supporting the beneficial effect of a low fructose diet on lipid profile, body weight, systolic and diastolic blood pressure, body fat, uric acid, triglycerides, fasting glucose, and insulin resistance in humans \[[@B42]\]. For example, a recent study found that obese children who had their fructose intake reduced showed a reduction in liver fat and an improvement in insulin kinetics \[[@B43]\]. Furthermore, in patients with nondiabetic chronic kidney disease stages 2 and 3, a low fructose diet exerted a decrease in uric acid, arterial blood pressure, and insulin concentration \[[@B44]\].

In a subanalysis of the Nurses\' Health Study using semiquantitative food frequency questionnaires to estimate diet composition, a higher dietary intake of animal fat and two or more servings per week of red meat were associated with an increased risk of microalbuminuria, and after adjustment for other nutrients individually associated with eGFR decline \>30%, only the highest quartile of sodium intake remained directly associated (OR: 1.52; 95% CI: 1.10 to 2.09), whereas *β*-carotene appeared protective (OR: 0.62, 95% CI: 0.43 to 0.89) \[[@B45]\]. Although we did not measure animal fat, red meat, or sodium intake, subjects with a high fructose intake (≥25 g/day) ingested less % of protein (16.9±3.2 % versus 19.3±4.7%, p = 0.002); the amount of %fat of the diet was similar between both groups: 36.5±9.6 versus 34±9.2, p 0.152.

The limitations of this study are that the exact content of free fructose in some processed foods could not be determined. For this reason, the amount of fructose was estimated dividing the sucrose content by 2. This may underestimate the real daily intake of fructose. Despite this, a significant positive association between fructose intake and albuminuria was found. Another limitation is that the cross-sectional design of the study does not permit inferring any causality between fructose intake and albuminuria, so additional prospective studies are needed to assess if low fructose diet could decrease albuminuria.

Another important limitation is that since all subjects consumed different types of fructose-containing foods, other nutrient factors contained in the diet that improve diabetes or insulin resistance (e.g., magnesium \[[@B46]\] or chromium\[[@B47]\]) were not considered and could be potential confounders of the study.

Another confounder factor that should be addressed in further longitudinal studies is that in our study subjects in the high fructose intake group also were the ones that had a higher intake in calories.

The strengths of this study are that we had a sufficient sample size to obtain statistically significant results; subjects underwent a comprehensive clinical and biochemical evaluation, in whom a prospective registry of food intake (the gold standard to calculate nutrient intake) during three days was performed to quantify the fructose intake. To our knowledge this is the first time fructose consumption was measured in patients in the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.

Further studies evaluating the effect of low fructose diets in reducing albuminuria and improving renal function in selected individuals are needed to warrant the implementation of preventive strategies. In summary, in subjects with T2DM we found a positive and independent association between fructose intake and albuminuria.
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Supplementary [Table 1](#tab1){ref-type="table"}: baseline characteristics of the subjects included in the study (n = 136). Supplementary [Table 2](#tab2){ref-type="table"}: calorie and fructose intake by sex. Supplementary [Table 3](#tab3){ref-type="table"}: albuminuria, fructose intake, and creatinine clearance stratified by sex.

###### 

Click here for additional data file.

![Flow chart of participants of the study.](IJN2018-5459439.001){#fig1}

![Association between fructose intake (g/day) and albuminuria (mg/day), obtained by Spearman correlation test (n=136).](IJN2018-5459439.002){#fig2}

![Association between fructose intake (g/day) and albuminuria (mg/day) in subjects with albuminuria between 30 to 3500 g/day, obtained by Spearman correlation test (n=86).](IJN2018-5459439.003){#fig3}
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###### 

Baseline characteristics of the subjects included in the study classified by fructose intake (n = 136).

  **Variable**                   **All**                  **Low fructose intake (**\<**25 g/day)**   **High fructose intake (**≥**25 g/day)**   **p**
  ------------------------------ ------------------------ ------------------------------------------ ------------------------------------------ -------
  Age, years                     59±8.79                  59±9.46                                    59±7.41                                    0.924
  Family history of T2DM         119, 87.5%               79, 87.8%                                  40, 87%                                    0.891
  Diabetes duration, years       16.5±7.8                 16±8                                       17±7                                       0.443
  Current smoking                25, 18.4%                16, 17.8%                                  9, 19.6%                                   0.799
  MAP, mmHg                      90.9±12.6                90±13.26                                   92±11.4                                    0.472
  BMI, kg/m^2^                   29.6±4.2                 29.8±4.2                                   29.3±4.2                                   0.558
  Waist circumference, cm        100.8±11.3               100.4±10.8                                 101.6±12.4                                 0.574
  WHR                            0.95±.08                 0.95±0.08                                  0.97±0.07                                  0.084
  Body fat, %                    32.7±8.2                 33.8±7.6                                   30.4±9                                     0.033
  Glucose, mg/dL                 154.8±64.0               151.9±61.34                                160.4±69.45                                0.462
  A1c, %                         8.9±1.8                  8.6±1.61                                   9.6±2.1                                    0.003
  Creatinine, mg/dL              0.95\[0.74-1.2\]         1.08±0.93                                  1.25±0.74                                  0.281
  BUN, mg/dL                     17.0 \[14-23.8\]         19.6\[13.6-21.3\]                          24.6\[15.5-27.6\]                          0.022
  Uric acid, mg/dL               6.6±1.8                  6.27±1.8                                   7.2±1.5                                    0.012
  Total cholesterol, mg/dL       173±38.4                 167.2±33.3                                 186.5±44.4                                 0.005
  Triglycerides, mg/dL           142.5 \[104.2- 189.7\]   162.3\[101.2-195.5\]                       166.6\[112.5-180.7\]                       0.936
  LDL-cholesterol, mg/dL         96.7±32.0                91.5±28.7                                  106.6±35.9                                 0.010
  HDL-cholesterol, mg/dL         45.9±11.4                45.1±10.6                                  47.5±12.7                                  0.230
  Creatinine clearance, mL/min   88.3±35.8                94.9±36.8                                  76.5±30.9                                  0.014
  Albuminuria, mg/day            87.3 \[16.4-385.5\]      60.8 \[12.8-228.5\]                        232.2 \[27.2 1273.0\]                      0.002
  Insulin use                    106, 77.9%               64, 71.1%                                  42, 91.3%                                  0.007
  Insulin dose, U/kg             40 \[24-53.2\]           43.6\[24.2-56.7\]                          40.1\[22.7-51.7\]                          0.747
  Metformin use                  112, 82.4%               78, 86.7%                                  34, 73.9%                                  0.065
  Sulfonylurea use               14, 10.3%                11, 12.2%                                  3, 6.5%                                    0.301
  DPP-4 inhibitor use            10, 7.4%                 6, 6.7%                                    4, 8.7%                                    0.668
  ACE inhibitor use              47, 34.6%                31, 34.4%                                  16, 34.8%                                  0.969
  ARB use                        17, 12.5%                9, 10%                                     8, 17.4%                                   0.218
  Aspirin use                    69, 50.7%                44, 48.9%                                  25, 54.3%                                  0.547
  Statin use                     74, 54.4%                51, 56.7%                                  23, 50%                                    0.460
  Fibrate use                    34, 25%                  26, 28.9%                                  8, 17.4%                                   0.143

Data is expressed as mean ± standard deviation, median \[interquartile range\], or numbers (percentage). P values obtained according to student T, U Mann-Whitney, or chi-squared tests as appropriate. MAP: mean arterial pressure, BMI: body mass index, WHR: waist to hip ratio, A1c: glycated hemoglobin, DPP-4: Dipeptidyl peptidase-4, ARB: angiotensin receptor blockers, ACE: angiotensin converting enzyme

###### 

Calorie and fructose intake in low and high fructose intake groups.

                            **All**             **Low fructose intake (\<25 g/day)**   **High fructose intake (≥25 g/day)**   **p**
  ------------------------- ------------------- -------------------------------------- -------------------------------------- ---------
  Total Calories kcal/day   1768±622.1          1585±558.4                             2125±588.9                             \<0.001
  Carbohydrates, %          45.6±11.9           43.9±12.3                              48.8±10.5                              0.022
  Proteins, %               18.5±4.4            19.3±4.7                               16.9±3.2                               0.002
  Fat, %                    35.7±9.5            36.5±9.6                               34±9.2                                 0.152
  Fructose, %               4.9 \[2.9-6.6\]     4.0\[2.3-5.1\]                         6.6\[5.4-8.2\]                         \<0.001
  Fructose intake, g/day    14.5 \[9.4-21.9\]   13.5\[9.1-20.2\]                       32.1\[28.1-43.8\]                      \<0.001

Data expressed as mean ± standard deviation or median \[interquartile range\]. P values obtained according to student T or U Mann-Whitney tests, as appropriate.

###### 

Correlation analyses between albuminuria and creatinine clearance with clinical and metabolic variables (n= 136).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variable**               **Albuminuria, ** **mg/day**\   **p**   **CKD-EPI,** **mL/min**\   **P**   **Measured creatinine clearance,** **mL/min**\   **p**
                             **rho**                                 **rho**                            **rho**                                          
  -------------------------- ------------------------------- ------- -------------------------- ------- ------------------------------------------------ -------
  Fructose intake, g/day     0.178                           0.038   -0.106                     0.221   -0.032                                           0.749

  Smoking, pack-years        0.191                           0.394   -0.173                     0.441   -0.086                                           0.719

  BMI, kg/m^2^               0.170                           0.048   -0.051                     0.558   0.073                                            0.473

  MAP, mmHg                  0.280                           0.001   -0.055                     0.526   -0.097                                           0.344

  A1c, %                     0.197                           0.022   -0.109                     0.207   -0.069                                           0.503

  Triglycerides, mg/dL       0.219                           0.010   -0.156                     0.069   -0.102                                           0.319

  Total cholesterol, mg/dL   0.138                           0.110   0.114                      0.188   -0.101                                           0.320

  HDL-c, mg/dL               -0.131                          0.127   0.048                      0.582   0.073                                            0.472

  LDL-c, mg/dL               0.084                           0.334   -0.018                     0.834   -0.083                                           0.418
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

p values obtained by Spearman correlation analyses. BMI: body mass index, MAP: mean arterial pressure, A1c: glycated hemoglobin

###### 

Correlation analyses in subjects with albuminuria between 30 and 3500 g/day (n=86).

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variable**               **Albuminuria, mg/day**  \   **p**   **CKD-EPI, mL/min**  \   **p**   **Measured creatinine clearance, mL/min**  \   **p**
                             **rho**                              **rho**                          **rho**                                        
  -------------------------- ---------------------------- ------- ------------------------ ------- ---------------------------------------------- --------
  Fructose intake, g/day     0.238                        0.027   0.091                    0.404   -0.322                                         0.013

  Smoking, pack-years        -0.370                       0.175   0.072                    0.800   0.154                                          0.616

  BMI, kg/m^2^               0.021                        0.851   -0.041                   0.707   0.164                                          0.215

  MAP, mmHg                  0.075                        0.491   0.082                    0.455   0.63                                           0.638

  A1c, %                     0.046                        0.675   .029                     0.788   -0.042                                         0.755

  Triglycerides, mg/dL       0.092                        0.398   -0.116                   0.288   0.117                                          0.378

  Total cholesterol, mg/dL   0.082                        0.455   -0.028                   0.797   -0.077                                         0.562

  HDL-c, mg/dL               -0.148                       0.174   0.051                    0.638   -0.022\                                        0.866\

  LDL-c, mg/dL               0.054                        0.625   0.049                    0.653   0.012                                          0.928
  --------------------------------------------------------------------------------------------------------------------------------------------------------

p values obtained by Spearman correlation analyses. BMI: body mass index, MAP: mean arterial pressure, A1c: glycated hemoglobin

###### 

Multiple linear regression analysis of variables associated with albuminuria in the subjects included in the study with albuminuria between 30 and 3500 mg/day (n = 86).

  **Variable**                   β         **t**   **p**
  ------------------------------ --------- ------- -------
  Constant                       -857.47   -1.20   0.23
  Fructose intake, g/day         13.96     2.82    0.006
  BMI, kg/m^2^                   19.30     1.24    0.219
  A1c, %                         23.84     0.585   0.560
  ACE inhibitor and/or ARB use   121.32    0.913   0.364
  MAP, mmHg                      1.842     0.349   0.728

Parameters of the model: r=0.36, r^2^=0.13, F=2.44, and p=0.041. BMI: body mass index, A1c: glycated hemoglobin, ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker, MAP: mean arterial pressure.

[^1]: Academic Editor: Franca Anglani
